Lance T Hall1,2, Benjamin Titz3, Nishanta Baidya3, Anja G van der Kolk3, H Ian Robins4,5,6,7, Mario Otto8, Scott B Perlman3,4, Jamey P Weichert3,4, John S Kuo4,5,9,10. 1. Department of Radiology, University of Wisconsin Hospitals and Clinics, MC 3252, 600 Highland Ave, Madison, WI, 53792, USA. lancehallmd@yahoo.com. 2. Carbone Cancer Center, University of Wisconsin, Madison, WI, USA. lancehallmd@yahoo.com. 3. Department of Radiology, University of Wisconsin Hospitals and Clinics, MC 3252, 600 Highland Ave, Madison, WI, 53792, USA. 4. Carbone Cancer Center, University of Wisconsin, Madison, WI, USA. 5. Department of Human Oncology, University of Wisconsin, Madison, WI, USA. 6. Department of Neurology, University of Wisconsin, Madison, WI, USA. 7. Department of Medicine, University of Wisconsin, Madison, WI, USA. 8. Department of Pediatrics, University of Wisconsin, Madison, WI, USA. 9. Department of Neurological Surgery, University of Wisconsin, Madison, WI, USA. 10. Department of Neurosurgery, The University of Texas at Austin, Austin, TX, USA.
Abstract
PURPOSE: There is a continuous search for imaging techniques with high sensitivity and specificity for brain tumors. Positron emission tomography (PET) imaging has shown promise, though many PET agents either have a low tumor specificity or impractical physical half-lives. [124I]CLR1404 is a small molecule alkylphosphocholine analogue that is thought to bind to plasma membrane lipid rafts and has shown high tumor-to-background ratios (TBR) in a previous pilot study in brain tumor patients. This study attempts to define the clinical value of [124I]CLR1404 PET/CT (aka CLR124). PROCEDURES: Adult patients with new or suspected recurrence of high-grade primary or metastatic brain tumors (N = 27) were injected with [124I]CLR1404 followed by PET/CT at 6, 24, and 48 h. Standard uptake values (SUV) and TBR values were calculated for all time points. Uptake of [124I]CLR1404 was qualitatively assessed, compared with magnetic resonance imaging (MRI), and correlated with clinical outcome. Final diagnosis (N = 25) was established based on surgically resected tissue or long-term follow-up. RESULTS: Positive uptake with high TBR was detected in all but one patient with a final diagnosis of primary/recurrent brain tumor (12/13) and in less than half of patients with treatment-related changes (5/12). Concordance between [124I]CLR1404 uptake and contrast enhancement on MRI was seen in < 40 %, with no concordance between T2-hyperintensities and uptake. No significant difference in overall outcome was found between patients with and without [124I]CLR1404 uptake. CONCLUSIONS: The uptake pattern in these patients suggests a very high sensitivity of [124I]CLR1404 PET/CT for diagnosing tumor tissue; however, tumor specificity needs to be further defined. Relative lack of concordance with standard MRI characteristics suggests that [124I]CLR1404 PET/CT provides additional information about brain tumors compared to MRI alone, potentially improving clinical decision-making.
PURPOSE: There is a continuous search for imaging techniques with high sensitivity and specificity for brain tumors. Positron emission tomography (PET) imaging has shown promise, though many PET agents either have a low tumor specificity or impractical physical half-lives. [124I]CLR1404 is a small molecule alkylphosphocholine analogue that is thought to bind to plasma membrane lipid rafts and has shown high tumor-to-background ratios (TBR) in a previous pilot study in brain tumorpatients. This study attempts to define the clinical value of [124I]CLR1404 PET/CT (aka CLR124). PROCEDURES: Adult patients with new or suspected recurrence of high-grade primary or metastatic brain tumors (N = 27) were injected with [124I]CLR1404 followed by PET/CT at 6, 24, and 48 h. Standard uptake values (SUV) and TBR values were calculated for all time points. Uptake of [124I]CLR1404 was qualitatively assessed, compared with magnetic resonance imaging (MRI), and correlated with clinical outcome. Final diagnosis (N = 25) was established based on surgically resected tissue or long-term follow-up. RESULTS: Positive uptake with high TBR was detected in all but one patient with a final diagnosis of primary/recurrent brain tumor (12/13) and in less than half of patients with treatment-related changes (5/12). Concordance between [124I]CLR1404 uptake and contrast enhancement on MRI was seen in < 40 %, with no concordance between T2-hyperintensities and uptake. No significant difference in overall outcome was found between patients with and without [124I]CLR1404 uptake. CONCLUSIONS: The uptake pattern in these patients suggests a very high sensitivity of [124I]CLR1404 PET/CT for diagnosing tumor tissue; however, tumor specificity needs to be further defined. Relative lack of concordance with standard MRI characteristics suggests that [124I]CLR1404 PET/CT provides additional information about brain tumors compared to MRI alone, potentially improving clinical decision-making.
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: Jamey P Weichert; Paul A Clark; Irawati K Kandela; Abram M Vaccaro; William Clarke; Marc A Longino; Anatoly N Pinchuk; Mohammed Farhoud; Kyle I Swanson; John M Floberg; Joseph Grudzinski; Benjamin Titz; Anne M Traynor; Hong-En Chen; Lance T Hall; Christopher J Pazoles; Perry J Pickhardt; John S Kuo Journal: Sci Transl Med Date: 2014-06-11 Impact factor: 17.956
Authors: Anatoly N Pinchuk; Mark A Rampy; Marc A Longino; R W Scott Skinner; Milton D Gross; Jamey P Weichert; Raymond E Counsell Journal: J Med Chem Date: 2006-04-06 Impact factor: 7.446
Authors: Kyle I Swanson; Paul A Clark; Ray R Zhang; Irawati K Kandela; Mohammed Farhoud; Jamey P Weichert; John S Kuo Journal: Neurosurgery Date: 2015-02 Impact factor: 4.654
Authors: Christian P Filss; Norbert Galldiks; Gabriele Stoffels; Michael Sabel; Hans J Wittsack; Bernd Turowski; Gerald Antoch; Ke Zhang; Gereon R Fink; Heinz H Coenen; Nadim J Shah; Hans Herzog; Karl-Josef Langen Journal: J Nucl Med Date: 2014-02-27 Impact factor: 10.057
Authors: Benoit J M Pirotte; Marc Levivier; Serge Goldman; Nicolas Massager; David Wikler; Olivier Dewitte; Michael Bruneau; Sandrine Rorive; Philippe David; Jacques Brotchi Journal: Neurosurgery Date: 2009-03 Impact factor: 4.654